“…phase I/II studies that have combined ifosfamide with other agents for treating advanced breast cancer patients, such as doxorubicin, (13) paclitaxel (14) and docetaxel (15,16) and these studies have demonstrated the feasibility of considerably high ifosfamide doses as well as the substantial activity of the employed combinations.…”